Patents Assigned to Fuso Pharmaceutical Industries, Ltd.
-
Publication number: 20110008431Abstract: The present invention provides a tablet for treating postherpetic neuralgia and a method of treating postherpetic neuralgia with the use of the tablet. The therapeutic tablet for postherpetic neuralgia according to the present invention is characterized in comprising buprenorphine hydrochloride, having a double layer structure consisting of a quick-release layer and a sustained-release layer, wherein the tablet is adhesive to the oral mucosa.Type: ApplicationFiled: March 14, 2008Publication date: January 13, 2011Applicants: TOYO BOSEKI KABUSHIKI KAISHA, FUSO PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Takuji Fukuno, Hiroshi Tachimori, Fuminori Mukunoki, Tadayo Miyasaka, Hiromasa Araki, Shuichi Tanaka, Shingo Doi, Shoichi Kawazoe
-
Patent number: 7807367Abstract: The present invention relates to a method for quickly determining cAMP content or an adenylate cyclase activity in a biological sample containing non-cyclic adenine nucleotides without the use of radioactive agents. Particularly, the present invention provides a method of determining CAMP content or an adenylate cyclase activity in a biological sample containing non-cyclic adenine nucleotides selected from the group consisting of cAMP produced by endogenous adenylate cyclase, and AMP, ATP, ADP and a mixture thereof, which comprises (1) combining a biological sample with effective amounts of apyrase, adenosine deaminase and alkaline phosphatase to enzymatically remove non-cyclic adenine nucleotides other than cAMP, and glucose-6-phosphate in the sample; (2) enzymatically converting cAMP into AMP; (3) determining an amount of AMP without the use of radioactive agents, and a kit to carry out the method.Type: GrantFiled: April 19, 2007Date of Patent: October 5, 2010Assignee: Fuso Pharmaceutical Industries, Ltd.Inventor: Atsushi Sugiyama
-
Patent number: 7723060Abstract: Methods for diagnosing renal disorder, hemolytic uremic syndrome and enterohemorrhagic E. coli infectious disease at an early stage, and for diagnosing the severity of these diseases are provided. Detection of excretion of AQP2 and/or molecules derived therefrom into urine of a subject, or determination of the amount of excretion of the same is conducted to diagnose the morbidity or the severity of renal disorder, hemolytic uremic syndrome and enterohemorrhagic E. coli infectious disease of the subject. For the detection and determination of AQP2, an immunochemical process may be suitably employed in which an antibody that specifically recognizes AQP2.Type: GrantFiled: February 29, 2008Date of Patent: May 25, 2010Assignee: Fuso Pharmaceutical Industries, Ltd.Inventors: Kunio Miwa, Junko Sugatani
-
Patent number: 7723061Abstract: Methods for diagnosing renal disorder, hemolytic uremic syndrome and enterohemorrhagic E. coli infectious disease at an early stage, and for diagnosing the severity of these diseases are provided. Detection of excretion of AQP2 and/or molecules derived therefrom into urine of a subject, or determination of the amount of excretion of the same is conducted to diagnose the morbidity or the severity of renal disorder, hemolytic uremic syndrome and enterohemorrhagic E. coli infectious disease of the subject. For the detection and determination of AQP2, an immunochemical process may be suitably employed in which an antibody that specifically recognizes AQP2.Type: GrantFiled: March 5, 2008Date of Patent: May 25, 2010Assignee: Fuso Pharmaceutical Industries, Ltd.Inventors: Kunio Miwa, Junko Sugatani
-
Publication number: 20100113749Abstract: Novel scavenger receptors having an SR structure and a collectin-like structure are provided, which can be utilized in the elucidation of mechanisms of macrophage and basic immunity; in the elucidation of mechanisms of the development of a wide variety of diseases such as arteriosclerosis, diabetic complications and Alzheimer's disease, hyper ?-lipoproteinemia, hypercholesterolemia, hypertriglyceridemia, hypo ?-lipoproteinemia, transplantation, atherectomy, post angiogenic restenosis, bacterial infections; in the diagnostic, prophylactic and therapeutic methods thereof; and in the development of reagents and drugs for the same. The novel scavenger receptors include proteins comprising an amino acid sequence set out in SEQ ID NO: 2, 4 or 24 or proteins having equivalent properties to the same, or derivatives or fragments thereof as well as isolated polynucleotides comprising a nucleotide sequence encoding these proteins, and related molecules such as antibodies, antagonists and the like.Type: ApplicationFiled: October 15, 2009Publication date: May 6, 2010Applicant: FUSO PHARMACEUTICAL INDUSTRIES, LTD.Inventor: Nobutaka Wakamiya
-
Publication number: 20100113750Abstract: Novel scavenger receptors having an SR structure and a collectin-like structure are provided, which can be utilized in the elucidation of mechanisms of macrophage and basic immunity; in the elucidation of mechanisms of the development of a wide variety of diseases such as arteriosclerosis, diabetic complications and Alzheimer's disease, hyper ?-lipoproteinemia, hypercholesterolemia, hypertriglyceridemia. hypo ?-lipoproteinemia, transplantation, atherectomy, post angiogenic restenosis, bacterial infections; in the diagnostic, prophylactic and therapeutic methods thereof; and in the development of reagents and drugs for the same. The novel scavenger receptors include proteins comprising an amino acid sequence set out in SEQ ID NO: 2, 4 or 24 or proteins having equivalent properties to the same, or derivatives or fragments thereof as well as isolated polynucleotides comprising a nucleotide sequence encoding these proteins, and related molecules such as antibodies, antagonists and the like.Type: ApplicationFiled: October 15, 2009Publication date: May 6, 2010Applicant: FUSO PHARMACEUTICAL INDUSTRIES, LTD.Inventor: NOBUTAKA WAKAMIYA
-
Publication number: 20100098757Abstract: The objective of the present invention is to provide a process for producing a buprenorphine pharmaceutical preparation to be applied to mouth mucosa. The process according to the present invention for producing a buprenorphine pharmaceutical preparation to be applied to mouth mucosa includes steps of: preparing a granule for an immediate-release layer containing a buprenorphine hydrochloride crystal having 90% cumulative diameter of 200 ?m or less; preparing a granule for a sustained-release layer containing a buprenorphine hydrochloride crystal having 90% cumulative diameter of 250 ?m or less; and tabletting the granule for the immediate-release layer and the granule for the sustained-release layer into a two-layer tablet.Type: ApplicationFiled: March 14, 2008Publication date: April 22, 2010Applicants: TOYO BOSEKI KABUSHIKI KAISHA, FUSO PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Fuminori Mukunoki, Tadayo Miyasaka
-
Patent number: 7651837Abstract: Causative microorganisms of infectious diseases are detected and/or identified rapidly and with high sensitivity by taking phagocytes from clinical specimens containing active phagocytes, immobilizing the phagocytes so taken, treating the phagocytes to improve cell membrane permeabilities thereof, further treating the phagocytes to bare DNA in the causative microorganisms which might exist in the phagocytes, and detecting the causative microorganisms with DNA probes which can hybridize with such DNA under stringent conditions.Type: GrantFiled: May 27, 2002Date of Patent: January 26, 2010Assignees: Fuso Pharmaceutical Industries, Ltd.Inventors: Tsuneya Ohno, Akio Matsuhisa
-
Publication number: 20090305341Abstract: Disclosed is the novel hCL-K1 polypeptide which offer collectin activity. This polypeptide consists of consecutive 271 amino acids set out in SEQ ID NO: 2 and does not bind to both maltose and N-acetylgalactosamine.Type: ApplicationFiled: April 5, 2007Publication date: December 10, 2009Applicants: FUSO PHARMACEUTICAL INDUSTRIES, LTD, ASAHIKAWA MEDICAL COLLEGEInventors: Nobutaka Wakamiya, Katsuki Otani, Takashi Sakamoto, Yuichiro Kishi, Hiroyuki Keshi, Aya Keshi
-
Publication number: 20090275740Abstract: Provided are isolated collectin (CL-L2s) genes including a base sequence set out in SEQ ID NO: 1, 3, 5, 7, 9, 12, 36, 38 or 40 relating to a novel collectin which are expected to exhibit an antibacterial activity, an antiviral activity and the like particularly in a human body; and isolated collectin proteins including an amino acid sequence set out in SEQ ID NO: 2, 4, 6, 8, 10, 13, 37, 39 or 41 and derivatives and fragments thereof.Type: ApplicationFiled: December 12, 2008Publication date: November 5, 2009Applicant: FUSO PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Nobutaka Wakamiya, Hiroyuki Keshi, Katsuki Ohtani, Takashi Sakamoto, Yuichiro Kishi
-
Patent number: 7612175Abstract: Novel scavenger receptors having an SR structure and a collectin-like structure are provided, which can be utilized in the elucidation of mechanisms of macrophage and basic immunity; in the elucidation of mechanisms of the development of a wide variety of diseases such as arteriosclerosis, diabetic complications and Alzheimer's disease, hyper ?-lipoproteinemia, hypercholesterolemia, hypertriglyceridemia, hypo ?-lipoproteinemia, transplantation, atherectomy, post angiogenic restenosis, bacterial infections; in the diagnostic, prophylactic and therapeutic methods thereof; and in the development of reagents and drugs for the same. The novel scavenger receptors include proteins comprising an amino acid sequence set out in SEQ ID NO: 2, 4 or 24 or proteins having equivalent properties to the same, or derivatives or fragments thereof as well as isolated polynucleotides comprising a nucleotide sequence encoding these proteins, and related molecules such as antibodies, antagonists and the like.Type: GrantFiled: March 12, 2007Date of Patent: November 3, 2009Assignee: Fuso Pharmaceutical Industries, Ltd.Inventor: Nobutaka Wakamiya
-
Patent number: 7612174Abstract: Novel scavenger receptors having an SR structure and a collectin-like structure are provided, which can be utilized in the elucidation of mechanisms of macrophage and basic immunity; in the elucidation of mechanisms of the development of a wide variety of diseases such as arteriosclerosis, diabetic complications and Alzheimer's disease, hyper ?-lipoproteinemia, hypercholesterolemia, hypertriglyceridemia, hypo ?-lipoproteinemia, transplantation, atherectomy, post angiogenic restenosis, bacterial infections; in the diagnostic, prophylactic and therapeutic methods thereof; and in the development of reagents and drugs for the same. The novel scavenger receptors include proteins comprising an amino acid sequence set out in SEQ ID NO: 2, 4 or 24 or proteins having equivalent properties to the same, or derivatives or fragments thereof as well as isolated polynucleotides comprising a nucleotide sequence encoding these proteins, and related molecules such as antibodies, antagonists and the like.Type: GrantFiled: March 12, 2007Date of Patent: November 3, 2009Assignee: Fuso Pharmaceutical Industries, Ltd.Inventor: Nobutaka Wakamiya
-
Patent number: 7572890Abstract: Recombinant Human Mannan-Binding Proteins (rhMBP) having physiological activities which are substantially identical to those offered by Human Mannan-Binding Proteins (hMBP), as well as, in particular, a production system for homogenously producing rhMBP having the specific peaks at the molecular weight of 1,000˜1,300 kDa determined by absorbance (280 nm) in Gel-Filtration Chromatography are provided.Type: GrantFiled: September 30, 2005Date of Patent: August 11, 2009Assignee: Fuso Pharmaceutical Industries, Ltd.Inventor: Nobutaka Wakamiya
-
Patent number: 7563594Abstract: The present inventors succeeded in cloning the CDT genes of C. coli and C. fetus, which were previously unknown, and in determining their sequences. In addition, the inventors also developed specific primers and primers common to the two species by comparing the CDTs of C. jejuni and C. fetus. Furthermore, the inventors demonstrated that these primers were applicable to multiplex PCR that simultaneously allows for the rapid and convenient determination of the presence of Campylobacter CDT and identification of species, and that they can also be used in PCR-RFLP-based typing.Type: GrantFiled: December 3, 2004Date of Patent: July 21, 2009Assignee: Fuso Pharmaceutical Industries, Ltd.Inventors: Shinji Yamasaki, Masahiro Asakura
-
Patent number: 7550437Abstract: The present invention provides a composition for safely and effectively preventing and treating digestive organs diseases, particularly, gastric ulcer, duodenal ulcer, gastritis, diarrhea, enteritis and the like. There is also provided a composition having a novel mechanism of action in order to solve the problems which was difficult to be solved by the side effect previously known mechanisms of action. More particularly, there is provided a pharmaceutical composition containing an ingredient which activates PAR-2 as an essential ingredient, which is useful for inhibiting gastric acid secretion, promoting digestive tract mucus secretion, protecting digestive tract mucosa, repairing tissue of digestive organs, and preventing and treating digestive organs diseases.Type: GrantFiled: January 3, 2006Date of Patent: June 23, 2009Assignee: Fuso Pharmaceutical Industries, Ltd.Inventors: Hiromasa Araki, Atsufumi Kawabata, Ryotaro Kuroda, Kazuaki Kakehi, Shuichi Tanaka, Kenzo Kawai, Sachiyo Nishimura, Hiroyuki Nishikawa
-
Publication number: 20090048165Abstract: Disclosed are anti-HIV agents which comprise a mannose binding protein (MBP) as an active component and are useful for effectively inhibiting progress of diseases state in and useful in therapy for individuals infected with human immunodeficiency virus (HIV). Also disclosed are a method for evaluating an anti-HIV activity of MBP comprising the step of culturing HIV infected cells under the presence of MBP.Type: ApplicationFiled: July 8, 2008Publication date: February 19, 2009Applicant: FUSO PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Nobutaka Wakamiya, Katsuki Ohtani, Takashi Sakamoto, Hiroyuki Keshi, Yuichiro Kishi
-
Publication number: 20080274483Abstract: Methods for diagnosing renal disorder, hemolytic uremic syndrome and enterohemorrhagic E. coli infectious disease at an early stage, and for diagnosing the severity of these diseases are provided. Detection of excretion of AQP2 and/or molecules derived therefrom into urine of a subject, or determination of the amount of excretion of the same is conducted to diagnose the morbidity or the severity of renal disorder, hemolytic uremic syndrome and enterohemorrhagic E. coli infectious disease of the subject. For the detection and determination of AQP2, an immunochemical process may be suitably employed in which an antibody that specifically recognizes AQP2.Type: ApplicationFiled: February 29, 2008Publication date: November 6, 2008Applicant: FUSO PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Kunio Miwa, Junko Sugatani
-
Publication number: 20080274484Abstract: Methods for diagnosing renal disorder, hemolytic uremic syndrome and enterohemorrhagic E. coli infectious disease at an early stage, and for diagnosing the severity of these diseases are provided. Detection of excretion of AQP2 and/or molecules derived therefrom into urine of a subject, or determination of the amount of excretion of the same is conducted to diagnose the morbidity or the severity of renal disorder, hemolytic uremic syndrome and enterohemorrhagic E. coli infectious disease of the subject. For the detection and determination of AQP2, an immunochemical process may be suitably employed in which an antibody that specifically recognizes AQP2.Type: ApplicationFiled: March 5, 2008Publication date: November 6, 2008Applicant: FUSO PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Kunio Miwa, Junko Sugatani
-
Patent number: 7358061Abstract: Antibodies to a LAR phosphatase subunit, particularly antibodies having specificity to an intracellular domain of a phosphatase subunit, methods for generation thereof and cells producing these antibodies, and determination and examination methods of LAR/LAR derived molecules using these antibodies, as well as uses of these antibodies in diagnosis and therapy of thyroid cancer are disclosed.Type: GrantFiled: September 21, 2004Date of Patent: April 15, 2008Assignee: Fuso PHarmaceutical Industries, Ltd.Inventors: Hiroshi Yamamoto, Kazutake Tsujikawa, Yukiko Uchino, Noboru Konishi
-
Patent number: 7351541Abstract: Methods for diagnosing renal disorder, hemolytic uremic syndrome and enterohemorrhagic E. coli infectious disease at an early stage, and for diagnosing the severity of these diseases are provided. Detection of excretion of AQP2 and/or molecules derived therefrom into urine of a subject, or determination of the amount of excretion of the same is conducted to diagnose the morbidity or the severity of renal disorder, hemolytic uremic syndrome and enterohemorrhagic E. coli infectious disease of the subject. For the detection and determination of AQP2, an immunochemical process may be suitably employed in which an antibody that specifically recognizes AQP2.Type: GrantFiled: October 6, 2000Date of Patent: April 1, 2008Assignee: Fuso Pharmaceutical Industries, Ltd.Inventors: Kunio Miwa, Junko Sugatani